Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation

Cancer

Volumn 119, Issue 18, 2013, Pages 3265-3271

  Nguyen, Quynh Nhu ^a   Levy, Lawrence B ^a   Lee, Andrew K ^a   Choi, Seungtaek S ^a   Frank, Steven J ^a   Pugh, Thomas J ^a   McGuire, Sean ^a   Hoffman, Karen ^a   Kuban, Deborah A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

androgen deprivation; disease control; external beam radiation; prostate cancer; survival

Indexed keywords

BICALUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER CLASSIFICATION; CANCER MORTALITY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LOCAL FAILURE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANDROGEN DEPRIVATION; DISEASE CONTROL; EXTERNAL BEAM RADIATION; PROSTATE CANCER; SURVIVAL;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NITRILES; ORCHIECTOMY; PANCREATIC NEOPLASMS; RADIATION TOLERANCE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK FACTORS; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84883599829     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28213     Document Type: Article

References (19)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011.
2. Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR,. The National Cancer Data Base report on prostate carcinoma after the peak incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998; 83: 1679-1684. (Pubitemid 28465487)
3. Hanks GE, Corn BW, Lee WR, Hunt M, Hanlon A, Schultheiss TE,. External beam irradiation of cancer of the prostate: conformal treatment techniques and outcomes for the 1990s. Cancer. 1995; 75 (Suppl S7): 1972-1977.
4. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53: 1097-1105. (Pubitemid 34787842)
5. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 67-74. (Pubitemid 350251041)
6. Hanks GE, Pajak TF, Porter A, et al. A phase III trial of long term adjuvant androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The RTOG protocol 92-02. J Clin Oncol. 2003; 21: 3972-3978. (Pubitemid 46606211)
7. Leibovici D, Lee AK, Cheung RM, et al. Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer. 2005; 103: 2060-2066. (Pubitemid 40605113)
8. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer. Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-974.
9. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290. (Pubitemid 40470408)
10. Pilepich MV, Winter K, John MF, et al. Phase III RTOG trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001; 50: 1243-1252. (Pubitemid 32727802)
11. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow up of a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer: RTOG 92-02. J Clin Oncol. 2008; 26: 2497-2504.
12. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet. 2002; 360: 103-106.
13. D'Amico AV, Chen M, Renshaw AA, et al. Androgen suppression and radiation vs. radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299: 289-295. (Pubitemid 351159365)
14. Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer: Who dies of disease? Int J Radiat Oncol Biol Phys. 2011; 79: 1310-1317.
15. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free suvival outcomes. Int J Radiat Oncol Biol Phys. 2008; 71: 1028-1033.
16. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high-dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006; 176: 1415-1419. (Pubitemid 44307191)
17. Kupelian P, Kuban DA, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005; 61: 415-419. (Pubitemid 40164435)
18. Zapatero A, Valcarcel F, Calva FA, et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol. 2005; 23: 6561-6568. (Pubitemid 46190249)
19. Bolla M, Gerrtjan VT, Padraig W, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol. 2010; 11: 1066-1073.